The JAK-STAT pathway plays a central role in chronic inflammatory diseases, such as rheumatoid arthritis (RA).1,2
In RA, inflammation is the major contributor to disability in early disease; radiographic progression dominates disability later in the disease process.3
Dysregulation of immune response ignites the uncontrolled inflammation of RA, which is fuelled by excessive signalling via the JAK-STAT pathway.1,5
HCP, healthcare provider; JAK, Janus kinase; RA, rheumatoid arthritis; STAT, signal transducer and activator of transcription.
REFERENCES
1. Malemud CJ. Integr J Mol Med. 2017;18(3). Pii:E484. 2. Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. Drugs. 2017;77(5):521-546. 3. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Rheumatology (Oxford). 2008;47(4):392-398. 4. Kirwan JR. J Rheumatol. 1999;26(3):720-725. 5. Hodge JA, et al. Clin Exp Rheumatol. 2016;34(2):318-328. 6. McInnes IB, Liew FY. Nat Clin Pract Rheumatol. 2005;1(1):31-39.
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© Galapagos Biopharma Sweden AB.
Vasagatan 7, 101 23 Stockholm, Sweden, VAT: SE559311454801. All rights reserved.
SE-RA-JY-202203-00001
GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos
NV.
© Galapagos Biopharma Sweden AB.
Vasagatan 7, 101 23 Stockholm, Sweden, VAT: SE559311454801. All rights reserved.
SE-RA-JY-202203-00001
© Copyright 2021 Galapagos NV
You are about to leave this website and will be redirected to an external website. We are not responsible of that external website’s content. By continuing, you confirm that you have taken note of this.
